Cabaletta Bio, Inc. (CABA) 10-Year Financial Performance & Capital Metrics

CABA • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutCabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Show more

Revenue $0
EBITDA -$120M -64.3%
Net Income -$116M -71.2%
EPS (Diluted) -2.34 -41.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -59.64% -50.1%
ROIC -361.32% -145.3%
Debt/Equity 0.10 +382.0%
Interest Coverage -167.30

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 81 (top 19%)
✓Trading at only 0.7x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 20.8% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-52.19%

EPS CAGR

10Y-

5Y-

3Y-

TTM-18.06%

ROCE

10Y Avg-40.27%

5Y Avg-44.51%

3Y Avg-51.52%

Latest-63.26%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	354K	733K	3.68M	1.43M	4.81M
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	0	0	-104K	-354K	-733K	-3.68M	-1.43M	-4.81M
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-2.4%	-1.07%	-4.03%	0.61%	-2.38%
Operating Expenses+	250K	6.19M	18.68M	33.48M	45.58M	50.45M	73.23M	120.33M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	250K	1.73M	7.01M	12.1M	13.09M	11.15M	19.24M	23.13M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	0	4.47M	11.67M	21.38M	32.49M	39.3M	55.42M	97.2M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	-1.43M	0
Operating Income+	-250K	-6.19M	-18.68M	-33.83M	-46.31M	-54.14M	-74.66M	-125.14M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-23.77%	-2.02%	-0.81%	-0.37%	-0.17%	-0.38%	-0.68%
EBITDA+	83.33K	0	-18.58M	-33.48M	-45.58M	-50.45M	-73.23M	-120.33M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-1%	-	-0.8%	-0.36%	-0.11%	-0.45%	-0.64%
D&A (Non-Cash Add-back)	333.33K	6.19M	104K	354K	733K	3.68M	1.43M	4.81M
EBIT	-250K	-12.2M	-18.68M	-33.34M	-46.29M	-52.98M	-67.67M	-115.12M
Net Interest Income+	0	0	1.74M	494K	24K	1.16M	6.99M	9.28M
Interest Income	0	235K	1.74M	494K	24K	1.16M	6.99M	10.03M
Interest Expense	0	0	0	0	0	0	0	748K
Other Income/Expense	0	-6.01M	1.74M	494K	24K	1.16M	6.99M	9.28M
Pretax Income+	-250K	-12.2M	-16.94M	-33.34M	-46.29M	-52.98M	-67.67M	-115.86M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-250K	-12.2M	-16.94M	-33.34M	-46.29M	-52.98M	-67.67M	-115.86M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	-47.81%	-0.39%	-0.97%	-0.39%	-0.14%	-0.28%	-0.71%
Net Income (Continuing)	-250K	-12.2M	-16.94M	-33.34M	-46.29M	-52.98M	-67.67M	-115.86M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.01	-0.84	-4.07	-1.44	-1.80	-1.81	-1.65	-2.34
EPS Growth %	-	-79.77%	-3.85%	0.65%	-0.25%	-0.01%	0.09%	-0.42%
EPS (Basic)	-0.01	-0.84	-4.07	-1.44	-1.80	-1.81	-1.65	-2.34
Diluted Shares Outstanding	24.03M	14.51M	5.47M	23.14M	25.74M	29.34M	40.95M	49.47M
Basic Shares Outstanding	24.03M	14.51M	4.16M	23.14M	25.74M	29.34M	40.95M	49.52M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1K	33.99M	140.55M	113.53M	124.54M	108.83M	244.49M	166.68M
Cash & Short-Term Investments	1K	33.02M	136.2M	108.66M	122.22M	106.55M	241.25M	163.96M
Cash Only	1K	33.02M	136.2M	101.43M	122.22M	81.61M	193.24M	163.96M
Short-Term Investments	0	0	0	7.23M	0	24.94M	48.01M	0
Accounts Receivable	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	2.76M	1.85M	1.97M	2.29M	0	2.71M
Total Non-Current Assets+	0	180K	916K	1.19M	1.79M	8.13M	9.16M	22.31M
Property, Plant & Equipment	0	0	815K	890K	1.44M	7.57M	7.45M	16.08M
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	180K	101K	299K	357K	565K	1.71M	6.23M
Total Assets+	1K	34.17M	141.47M	114.72M	126.34M	116.97M	253.65M	185.05M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	34173%	3.14%	-0.19%	0.1%	-0.07%	1.17%	-0.27%
Total Current Liabilities+	250K	943K	3.15M	5.18M	8.38M	9.49M	15.99M	27.09M
Accounts Payable	189K	603K	920K	1.24M	2.33M	2.46M	4.55M	4.92M
Days Payables Outstanding	-	-	-	1.28K	1.16K	244.03	1.16K	373.34
Short-Term Debt	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	12K	219K	705K	38K	3.07M	1.33M	40K	8.36M
Current Ratio	0.00x	36.05x	44.66x	21.92x	14.86x	11.47x	15.29x	6.15x
Quick Ratio	0.00x	36.05x	44.66x	21.92x	14.86x	11.47x	15.29x	6.15x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	189K	43.92M	920K	0	0	2.96M	1.46M	5.63M
Long-Term Debt	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	2.96M	1.46M	5.63M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0
Total Liabilities	250K	44.86M	3.15M	5.18M	8.38M	12.45M	17.45M	32.71M
Total Debt+	0	43.92M	0	0	0	5.14M	5.02M	15.6M
Net Debt	-1K	10.9M	-136.2M	-101.43M	-122.22M	-76.47M	-188.22M	-148.36M
Debt / Equity	-	-	-	-	-	0.05x	0.02x	0.10x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-0.01x	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-167.30x
Total Equity+	-249K	-10.69M	138.32M	109.54M	117.96M	104.52M	236.2M	152.34M
Equity Growth %	-	-41.93%	13.94%	-0.21%	0.08%	-0.11%	1.26%	-0.36%
Book Value per Share	-0.01	-0.74	25.29	4.73	4.58	3.56	5.77	3.08
Total Shareholders' Equity	-249K	-10.69M	138.32M	109.54M	117.96M	104.52M	236.2M	152.34M
Common Stock	0	0	0	0	0	0	0	1K
Retained Earnings	-250K	-12.45M	-32.96M	-66.3M	-112.59M	-165.56M	-233.24M	-349.1M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	6K	0	-47K	39K	0
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	0	-4.66M	-16.05M	-26.77M	-34.11M	-46.38M	-53.55M	-88.22M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-	-2.44%	-0.67%	-0.27%	-0.36%	-0.15%	-0.65%
Net Income	-333.33K	-12.2M	-16.94M	-33.34M	-46.29M	-52.98M	-67.67M	-115.86M
Depreciation & Amortization	0	0	104K	354K	733K	1.18M	1.43M	1.71M
Stock-Based Compensation	0	606K	2.3M	4.39M	5.8M	6.9M	11.34M	19.46M
Deferred Taxes	0	0	-2.26M	0	0	0	0	0
Other Non-Cash Items	252K	7.4M	2.26M	119K	62K	2.82M	1.26M	4.86M
Working Capital Changes	81.33K	-464K	-1.51M	1.71M	5.58M	-4.3M	101K	1.61M
Change in Receivables	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	0	234K	246K	555K	975K	-28K	1.68M	1.01M
Cash from Investing+	0	0	-693K	-7.98M	6M	-27.22M	-22.45M	47.29M
Capital Expenditures	0	0	-693K	-635K	-1.17M	-2.45M	-687K	-2.21M
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	-7.35K	0	-24.76K	0	0
Cash from Financing+	1.33K	37.68M	119.92M	-24K	48.9M	32.98M	187.63M	11.68M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	-10.09M	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	1.33K	-169K	8.8M	168K	650K	127K	2.43M	1.7M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	0	-4.66M	-16.74M	-27.41M	-35.27M	-48.83M	-54.24M	-90.43M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	-	-2.59%	-0.64%	-0.29%	-0.38%	-0.11%	-0.67%
FCF per Share	-	-0.32	-3.06	-1.18	-1.37	-1.66	-1.32	-1.83
FCF Conversion (FCF/Net Income)	-	0.38x	0.95x	0.80x	0.74x	0.88x	0.79x	0.76x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-26.55%	-26.9%	-40.69%	-47.62%	-39.72%	-59.64%
Return on Invested Capital (ROIC)	-	-	-1202.25%	-495.99%	-1804.87%	-341.43%	-147.3%	-361.32%
Debt / Equity	-	-	-	-	-	0.05x	0.02x	0.10x
Interest Coverage	-	-	-	-	-	-	-	-167.30x
FCF Conversion	-	0.38x	0.95x	0.80x	0.74x	0.88x	0.79x	0.76x

Frequently Asked Questions

Growth & Financials

Cabaletta Bio, Inc. (CABA) grew revenue by 0.0% over the past year. Growth has been modest.

Cabaletta Bio, Inc. (CABA) reported a net loss of $158.5M for fiscal year 2024.

Dividend & Returns

Cabaletta Bio, Inc. (CABA) has a return on equity (ROE) of -59.6%. Negative ROE indicates the company is unprofitable.

Cabaletta Bio, Inc. (CABA) had negative free cash flow of $120.3M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Cabaletta Bio, Inc. (CABA) 10-Year Financial Performance & Capital Metrics

CABA • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $0
EBITDA -$120M -64.3%
Net Income -$116M -71.2%
EPS (Diluted) -2.34 -41.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -59.64% -50.1%
ROIC -361.32% -145.3%
Debt/Equity 0.10 +382.0%
Interest Coverage -167.30

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 81 (top 19%)
✓Trading at only 0.7x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 20.8% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-52.19%

EPS CAGR

10Y-

5Y-

3Y-

TTM-18.06%

ROCE

10Y Avg-40.27%

5Y Avg-44.51%

3Y Avg-51.52%

Latest-63.26%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	354K	733K	3.68M	1.43M	4.81M
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	0	0	-104K	-354K	-733K	-3.68M	-1.43M	-4.81M
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-2.4%	-1.07%	-4.03%	0.61%	-2.38%
Operating Expenses+	250K	6.19M	18.68M	33.48M	45.58M	50.45M	73.23M	120.33M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	250K	1.73M	7.01M	12.1M	13.09M	11.15M	19.24M	23.13M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	0	4.47M	11.67M	21.38M	32.49M	39.3M	55.42M	97.2M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	-1.43M	0
Operating Income+	-250K	-6.19M	-18.68M	-33.83M	-46.31M	-54.14M	-74.66M	-125.14M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-23.77%	-2.02%	-0.81%	-0.37%	-0.17%	-0.38%	-0.68%
EBITDA+	83.33K	0	-18.58M	-33.48M	-45.58M	-50.45M	-73.23M	-120.33M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-1%	-	-0.8%	-0.36%	-0.11%	-0.45%	-0.64%
D&A (Non-Cash Add-back)	333.33K	6.19M	104K	354K	733K	3.68M	1.43M	4.81M
EBIT	-250K	-12.2M	-18.68M	-33.34M	-46.29M	-52.98M	-67.67M	-115.12M
Net Interest Income+	0	0	1.74M	494K	24K	1.16M	6.99M	9.28M
Interest Income	0	235K	1.74M	494K	24K	1.16M	6.99M	10.03M
Interest Expense	0	0	0	0	0	0	0	748K
Other Income/Expense	0	-6.01M	1.74M	494K	24K	1.16M	6.99M	9.28M
Pretax Income+	-250K	-12.2M	-16.94M	-33.34M	-46.29M	-52.98M	-67.67M	-115.86M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-250K	-12.2M	-16.94M	-33.34M	-46.29M	-52.98M	-67.67M	-115.86M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	-47.81%	-0.39%	-0.97%	-0.39%	-0.14%	-0.28%	-0.71%
Net Income (Continuing)	-250K	-12.2M	-16.94M	-33.34M	-46.29M	-52.98M	-67.67M	-115.86M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.01	-0.84	-4.07	-1.44	-1.80	-1.81	-1.65	-2.34
EPS Growth %	-	-79.77%	-3.85%	0.65%	-0.25%	-0.01%	0.09%	-0.42%
EPS (Basic)	-0.01	-0.84	-4.07	-1.44	-1.80	-1.81	-1.65	-2.34
Diluted Shares Outstanding	24.03M	14.51M	5.47M	23.14M	25.74M	29.34M	40.95M	49.47M
Basic Shares Outstanding	24.03M	14.51M	4.16M	23.14M	25.74M	29.34M	40.95M	49.52M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1K	33.99M	140.55M	113.53M	124.54M	108.83M	244.49M	166.68M
Cash & Short-Term Investments	1K	33.02M	136.2M	108.66M	122.22M	106.55M	241.25M	163.96M
Cash Only	1K	33.02M	136.2M	101.43M	122.22M	81.61M	193.24M	163.96M
Short-Term Investments	0	0	0	7.23M	0	24.94M	48.01M	0
Accounts Receivable	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	2.76M	1.85M	1.97M	2.29M	0	2.71M
Total Non-Current Assets+	0	180K	916K	1.19M	1.79M	8.13M	9.16M	22.31M
Property, Plant & Equipment	0	0	815K	890K	1.44M	7.57M	7.45M	16.08M
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	180K	101K	299K	357K	565K	1.71M	6.23M
Total Assets+	1K	34.17M	141.47M	114.72M	126.34M	116.97M	253.65M	185.05M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	34173%	3.14%	-0.19%	0.1%	-0.07%	1.17%	-0.27%
Total Current Liabilities+	250K	943K	3.15M	5.18M	8.38M	9.49M	15.99M	27.09M
Accounts Payable	189K	603K	920K	1.24M	2.33M	2.46M	4.55M	4.92M
Days Payables Outstanding	-	-	-	1.28K	1.16K	244.03	1.16K	373.34
Short-Term Debt	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	12K	219K	705K	38K	3.07M	1.33M	40K	8.36M
Current Ratio	0.00x	36.05x	44.66x	21.92x	14.86x	11.47x	15.29x	6.15x
Quick Ratio	0.00x	36.05x	44.66x	21.92x	14.86x	11.47x	15.29x	6.15x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	189K	43.92M	920K	0	0	2.96M	1.46M	5.63M
Long-Term Debt	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	2.96M	1.46M	5.63M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0
Total Liabilities	250K	44.86M	3.15M	5.18M	8.38M	12.45M	17.45M	32.71M
Total Debt+	0	43.92M	0	0	0	5.14M	5.02M	15.6M
Net Debt	-1K	10.9M	-136.2M	-101.43M	-122.22M	-76.47M	-188.22M	-148.36M
Debt / Equity	-	-	-	-	-	0.05x	0.02x	0.10x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-0.01x	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-167.30x
Total Equity+	-249K	-10.69M	138.32M	109.54M	117.96M	104.52M	236.2M	152.34M
Equity Growth %	-	-41.93%	13.94%	-0.21%	0.08%	-0.11%	1.26%	-0.36%
Book Value per Share	-0.01	-0.74	25.29	4.73	4.58	3.56	5.77	3.08
Total Shareholders' Equity	-249K	-10.69M	138.32M	109.54M	117.96M	104.52M	236.2M	152.34M
Common Stock	0	0	0	0	0	0	0	1K
Retained Earnings	-250K	-12.45M	-32.96M	-66.3M	-112.59M	-165.56M	-233.24M	-349.1M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	6K	0	-47K	39K	0
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	0	-4.66M	-16.05M	-26.77M	-34.11M	-46.38M	-53.55M	-88.22M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-	-2.44%	-0.67%	-0.27%	-0.36%	-0.15%	-0.65%
Net Income	-333.33K	-12.2M	-16.94M	-33.34M	-46.29M	-52.98M	-67.67M	-115.86M
Depreciation & Amortization	0	0	104K	354K	733K	1.18M	1.43M	1.71M
Stock-Based Compensation	0	606K	2.3M	4.39M	5.8M	6.9M	11.34M	19.46M
Deferred Taxes	0	0	-2.26M	0	0	0	0	0
Other Non-Cash Items	252K	7.4M	2.26M	119K	62K	2.82M	1.26M	4.86M
Working Capital Changes	81.33K	-464K	-1.51M	1.71M	5.58M	-4.3M	101K	1.61M
Change in Receivables	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	0	234K	246K	555K	975K	-28K	1.68M	1.01M
Cash from Investing+	0	0	-693K	-7.98M	6M	-27.22M	-22.45M	47.29M
Capital Expenditures	0	0	-693K	-635K	-1.17M	-2.45M	-687K	-2.21M
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	-7.35K	0	-24.76K	0	0
Cash from Financing+	1.33K	37.68M	119.92M	-24K	48.9M	32.98M	187.63M	11.68M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	-10.09M	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	1.33K	-169K	8.8M	168K	650K	127K	2.43M	1.7M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	0	-4.66M	-16.74M	-27.41M	-35.27M	-48.83M	-54.24M	-90.43M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	-	-2.59%	-0.64%	-0.29%	-0.38%	-0.11%	-0.67%
FCF per Share	-	-0.32	-3.06	-1.18	-1.37	-1.66	-1.32	-1.83
FCF Conversion (FCF/Net Income)	-	0.38x	0.95x	0.80x	0.74x	0.88x	0.79x	0.76x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-26.55%	-26.9%	-40.69%	-47.62%	-39.72%	-59.64%
Return on Invested Capital (ROIC)	-	-	-1202.25%	-495.99%	-1804.87%	-341.43%	-147.3%	-361.32%
Debt / Equity	-	-	-	-	-	0.05x	0.02x	0.10x
Interest Coverage	-	-	-	-	-	-	-	-167.30x
FCF Conversion	-	0.38x	0.95x	0.80x	0.74x	0.88x	0.79x	0.76x

Frequently Asked Questions

Growth & Financials

Cabaletta Bio, Inc. (CABA) grew revenue by 0.0% over the past year. Growth has been modest.

Cabaletta Bio, Inc. (CABA) reported a net loss of $158.5M for fiscal year 2024.

Dividend & Returns

Cabaletta Bio, Inc. (CABA) has a return on equity (ROE) of -59.6%. Negative ROE indicates the company is unprofitable.

Cabaletta Bio, Inc. (CABA) had negative free cash flow of $120.3M in fiscal year 2024, likely due to heavy capital investments.